GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » Institutional Ownership

SciSparc (SciSparc) Institutional Ownership : 0.01% (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is SciSparc Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SciSparc's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SciSparc's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SciSparc's Float Percentage Of Total Shares Outstanding is 0.00%.


SciSparc Institutional Ownership Historical Data

The historical data trend for SciSparc's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciSparc Institutional Ownership Chart

SciSparc Historical Data

The historical data trend for SciSparc can be seen below:

2020-10-31 2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-03-31 2021-04-30 2021-05-31 2021-06-30 2021-07-31
Institutional Ownership 0.07 0.07 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

SciSparc Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SciSparc (SciSparc) Business Description

Traded in Other Exchanges
Address
20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.